title: Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
abstract: Chimeric antigen receptors (CARs) are recombinant receptors that combine the specificity of an antigen-specific antibody with the T-cell's activating functions. Initial clinical trials of genetically engineered CAR T cells have significantly raised the profile of T cell therapy, and great efforts have been made to improve this approach. In this review, we provide a structural overview of the development of CAR technology and highlight areas that require further refinement. We also discuss critical issues related to CAR therapy, including the optimization of CAR T cells, the route of administration, CAR toxicity and the blocking of inhibitory molecules.
authors.forename: Huan
authors.initials: H
authors.lastname: Shi
authors.forename: Meili
authors.initials: M
authors.lastname: Sun
authors.affiliation: Department of Oncology, Shandong Cancer Hospital and Institute, No, 440 Jiyan Road, Jinan, Shandong 250117, P,R, China. linliu1028@gmail.com.
authors.forename: Lin
authors.initials: L
authors.lastname: Liu
authors.forename: Zhehai
authors.initials: Z
authors.lastname: Wang
mesh_terms: D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins